低剂量化疗作用机制的研究进展

doi:10.11904/j.issn.1002-3070.2017.06.011

摘要/Abstract

摘要： 化疗是肿瘤综合治疗的主要方式之一,多年来在肿瘤治疗中发挥着重要作用。但近年来低剂量化疗(Low-dose chemotherapy)利用其化疗药物的作用点,采取合理的给药方式和计划,且相对于最大耐受剂量化疗具有毒副反应小、患者耐受性明显提高、疗效更佳等优势,已逐渐成为临床中常用的治疗策略。本文就低剂量化疗的作用机制的研究进展做一系统综述。

关键词: 低剂量化疗, 抗血管生成, 细胞凋亡

Abstract: Chemotherapy is one of the main ways for comprehensive treatment of tumors,and has played an important role in tumor treatment for many years.However,in recent years,low-dose chemotherapy(Low-dose chemotherapy) has gradually become a clinical treatment strategy commonly used to taken a reasonable mode of administration and planning,relative to the maximum tolerated dose of chemotherapy with small side effects,patient tolerance significantly improved,better efficacy and other.In this paper,the mechanism of low-dose chemotherapy on the progress is reviewed systematicly.

Key words: Low-dose chemotherapy, Anti-angiogenesis, Cell apoptosis

中图分类号:

R730.53

梁语丝, 谭永刚, 邹华伟审校. 低剂量化疗作用机制的研究进展[J]. 实用肿瘤学杂志, 2017, 31(6): 538-542.

LIANG Yusi, TAN Yonggang, ZOU Huawei. Research progress on mechanism of low-dose chemotherapy[J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(6): 538-542.

参考文献

1 Lien K,Georgsdottir S,Emmenegger L,et al.Low-dose metronomic chemotherapy:A systematic literature analysis[J].Eur J Cancer,2013,49:3387-3395.
2 Simkens LH,van Tinteren H,May A,et al.Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer(CAIRO3):a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group[J].Lancet,2015,385(9980):1843-1852.
3 Pasquier E,Kavallaris M,Andre N,et al.Metronomic chemotherapy:new rationale for new directions[J].Nat Rev Clin Oncol,2010,7(8):455-465.
4 Xie X,Wu Y,Luo S,et al.Efficacy and toxicity of low-dose versus conventional-dose chemotherapy for malignant tumors:a meta-analysis of 6 randomized controlled trials[J].Asian Pac J Cancer Prev,2017,18(2):479-484.
5 Montagna E,Cancello G,Dellapasqua S,et al.Metronomic therapy and breast cancer:a systematic review[J].Cancer Treat Rev,2014,40(8):942-950.
6 Kobayashi N,Nakayama H,Osaka Y,et al.Tumor response after low-dose preoperative radiotherapy combined with chemotherapy for squamous cell esophageal carcinoma[J].Anticancer Res,2013,33(3):1157-1161.
7 Munzone E,Colleoni M.Clinical overview of metronomic chemotherapy in breast cancer[J].Nat Rev Clin Oncol,2015,12(11):631-644.
8 Camacho KM,Menegatti S,Vogus DR,et al.DAFODIL:A novel liposome-encapsulated synergistic combination of doxorubicin and 5FU for low dose chemotherapy[J].J Control Release,2016,229:154-162.
9 Moesa J,Koolena S,Huitema A,et al.Development of an oral solid dispersion formulation for use in low-dose metronomic chemotherapy of paclitaxel[J].Eur J Pharm Biopharm,2013,83(1):87-94.
10 Jedeszko C,Paez-Ribes M,Di Desidero T,et al.Postsurgical adjuvant or metastatic renal cell carcinoma therapy models reveal potent antitumor activity of metronomic oral topotecan with pazopanib[J].Sci Transl Med,2015,7(282):282ra50.
11 Zhu H,Zhao F,Yu S,et al.The synergistic effects of low-dose irinotecan and TRAIL on TRAIL-resistant HT-29 colon carcinoma in vitro and in vivo[J].Int J Mol Med,2012,30(5):1087-1094.
12 Lee SC,Cheong HJ,Kim SJ,et al.Low-dose combinations of LBH589 and TRAIL can overcome TRAIL-resistance in colon cancer cell lines[J].Anticancer Res,2011,31(10):3385-3394.
13 Teramoto M,Suzuki T,Satohisa S,et al.Low-dose SN-38 with paclitaxel induces lethality in human uterine cervical adenocarcinoma cells by increasing caspase activity[J].Med Mol Morphol,2014,47(1):31-37.
14 Eom YW,Kim MA,Park SS,et al.Two distinct modes of cell death induced by doxorubicin:apoptosis and cell death through mitotic catastrophe accompanied by senescence-like phenotype[J].Oncogene,2005,24(30):4765-4777.
15 Park SS,Kim MA,Eom YW,et al.Bcl-xL blocks high dose doxorubicin-induced apoptosis but not low dose doxorubicin-induced cell death through mitotic catastrophe[J].Biochem Bioph Res Co,2007,363(4):1044-1049.
16 Stoelting S,Trefzer T,Kisro J,et al.Low-dose oral metronomic chemotherapy prevents mobilization of endothelial progenitor cells into the blood of cancer patients[J].In vivo,2008,22(22):831-836.
17 Zhou F,Hu J,Shao JH,et al.Metronomic chemotherapy in combination with antiangiogenic treatment induces mosaic vascular reduction and tumor growth inhibition in hepatocellular carcinoma xenografts[J].J Cancer Res Clin Oncol,2012,138(11):1879-1890.
18 Wu H,Xin Y,Xiao Y,et al.Low-dose docetaxel combined with(-)-epigallocatechin-3-gallate inhibits angiogenesis and tumor growth in nude mice with gastric cancer xenografts[J].Cancer Biother Radiopharm,2012,27(3):204-209.
19 Kontopodis E,Hatzidaki D,Varthalitis I,et al.A phase II study of metronomic oral vinorelbine administered in the second line and beyond in non-small cell lung cancer(NSCLC):a phase II study of the Hellenic Oncology Research Group[J].J Chemother,2013,25(1):49-55.
20 Albertsson P,Lennerns B,Norrby K.Low-dosage metronomic chemotherapy and angiogenesis:topoisomerase inhibitors irinotecan and mitoxantrone stimulate VEGF-A-mediated angiogenesis[J].APMIS,2012,120(2):147-156.
21 Francia G,Shaked Y,Hashimoto K,et al.Low-dose metronomic oral dosing of a prodrug of gemcitabine(LY2334737)causes antitumor effects in the absence of inhibition of systemic vasculogenesis[J].Mol Cancer Ther,2012,11(3):680-689.
22 Akiyama K,Maishi N,Ohga N,et al.Inhibition of multidrug transporter in tumor endothelial cells enhances antiangiogenic effects of low-dose metronomic Paclitaxel[J].Am J Pathol,2015,185(2):572-580.
23 Dong M,Liang D,Li Y,et al.Autologous dendritic cells combined with cytokine-induced killer cells synergize low-dose chemotherapy in elderly patients with acute myeloid leukaemia[J].J Int Med Res,2012,40(4):1265-1274.
24 He Q,Li J,Yin W,et al.Low-dose paclitaxel enhances the anti-tumor efficacy of GM-CSF surface-modified whole-tumor-cell vaccine in mouse model of prostate cancer[J].Cancer Immunol Immunother,2011,60(5):715-730.
25 Michels T,Shurin GV,Naiditch H,et al.Paclitaxel promotes differentiation of myeloid-derived suppressor cells into dendritic cells in vitro in a TLR4-independent manner[J].J Immunotoxicol,2012,9(3):292-300.
26 Lee JM,Seo JH,Kim YJ,et al.The restoration of myeloid-derived suppressor cells as functional antigen-presenting cells by NKT cell help and all-trans-retinoic acid treatment[J].Int J Cancer,2012,131(3):741-751.
27 Radojcic V,Bezak KB,Skarica M,et al.Cyclophosphamide resets dendritic cell homeostasis and enhances antitumor immunity through effects that extend beyond regulatory T cell elimination[J].Cancer Immunol Immunother,2010,59(1):137-148.
28 Dewan MZ,Vanpouillebox C,Kawashima N,et al.Synergy of topical toll-like receptor 7 agonist with radiation and low-dose cyclophosphamide in a mouse model of cutaneous breast cancer[J].Clin Cancer Res,2012,18(24):6668-6678.
29 Tongu M,Harashima N,Monma H,et al.Metronomic chemotherapy with low-dose cyclophosphamide plus gemcitabine can induce anti-tumor T cell immunity in vivo[J].Cancer Immunol Immunother,2013,62(2):383-391.
30 Triozzi PL,Aldrich W,Achberger S,et al.Differential effects of low-dose decitabine on immune effector and suppressor responses in melanoma-bearing mice[J].Cancer Immunol Immunother,2012,61(9):1441-1450.
31 Nars MS,Kaneno R.Immunomodulatory effects of low dose chemotherapy and perspectives of its combination with immunotherapy[R].Int J Cancer,2013,132(11):2471-2478.
32 Shaked Y,Pham E,Hariharan S,et al.Evidence implicating immunological host effects in the efficacy of metronomic low-dose chemotherapy[J].Cancer Res,2016,76(20):5983-5993.
33 Chan TS,Hsu CC,Pai VC,et al.Metronomic chemotherapy prevents therapy-induced stromal activation and induction of tumor-initiating cells[J].J Exp Med,2016,213(13):2967-2988.
34 Srivastava K,Hu J,Korn C,et al.Postsurgical adjuvant tumor therapy by combining anti-angiopoietin-2 and metronomic chemotherapy limits metastatic growth[J].Cancer Cell,2014,26(6):880-895.
35 Folkins C,Man S,Xu P,et al.Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors[J].Cancer Res,2007,67(8):3560-3564.
36 Hashimoto K,Man S,Xu P,et al.Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer[J].Mol Cancer Ther,2010,9(4):996-1006.
37 Akladios FN,Andrew SD,Parkinson CJ.Selective induction of oxidative stress in cancer cells via synergistic combinations of agents targeting redox homeostasis[J].Bioorg Med Chem,2015,23(13):3097-3104.

[1]	王吉锡, 邓伟生, 王凤儒, 史之茂, 孟丹, 徐强, 张玉瑶. 甘草提取物的有效部位诱导人宫颈癌HeLa细胞株凋亡及对凋亡相关蛋白Caspase-3和Caspase-9表达的影响[J]. 实用肿瘤学杂志, 2017, 31(5): 390-395.
[2]	代欣综述, 张大昕审校. 非小细胞肺癌抗血管生成治疗研究现状[J]. 实用肿瘤学杂志, 2017, 31(5): 472-476.
[3]	张绪良, 胡亚华, 黄丹青. 苏林酸在NF-κB对人乳腺癌TNF-α诱导细胞凋亡增敏中的相关作用[J]. 实用肿瘤学杂志, 2017, 31(2): 102-106.
[4]	刘冰梅, 程雪, 邢荣贵综述, 杨晶审校. 角化棘皮瘤消退机制的研究进展[J]. 实用肿瘤学杂志, 2017, 31(1): 83-87.
[5]	赵相轩, 温锋, 毛晓楠综述, 卢再鸣审校. 细胞凋亡在原发性肝癌治疗中的作用研究进展[J]. 实用肿瘤学杂志, 2016, 30(5): 448-452.
[6]	赵相轩,温锋综述,卢再鸣审校. 细胞凋亡在胰腺癌治疗中的作用[J]. 实用肿瘤学杂志, 2016, 30(4): 375-379.
[7]	郑育强, 丁锦辉, 宋磊. 增强细胞缝隙连接功能对三阴性乳腺癌细胞放疗敏感性的研究[J]. 实用肿瘤学杂志, 2016, 30(2): 128-134.
[8]	李富荣,程先硕,李云峰. 靶向血管生成拟态治疗肿瘤的研究进展[J]. 实用肿瘤学杂志, 2015, 29(4): 359-363.
[9]	赵云, 温锋, 赵相轩, 郭启勇. TRAIL及其相关凋亡调节机制在胆管癌中的研究进展[J]. 实用肿瘤学杂志, 2015, 29(1): 49-52.
[10]	张天华, 李永春, 李宪伟, 迟德财. C2-神经酰胺对人间皮瘤细胞凋亡的诱导作用[J]. 实用肿瘤学杂志, 2014, 28(6): 492-497.
[11]	刘跃欣, 周琪, 闫金银综述, 胡万宁审校. 蒜素抗肿瘤的研究进展[J]. 实用肿瘤学杂志, 2014, 28(6): 557-560.
[12]	张纪妍, 陈杰, 郭兴罡. 四硫化四砷对人卵巢癌裸鼠皮下移植瘤抑瘤作用的研究[J]. 实用肿瘤学杂志, 2012, 26(5): 418-422.
[13]	栾天, 佟雷, 徐威, 钟照华. MiR-122促进原发性肝细胞癌Huh-7细胞凋亡[J]. 实用肿瘤学杂志, 2012, 26(5): 428-431.
[14]	宋凯镔, 王文波. Fe₃O₄-As₂O₃-PLA复合体联合热疗对骨肉瘤治疗的细胞学研究[J]. 实用肿瘤学杂志, 2012, 26(5): 438-442.
[15]	贾树钊, 杨树萌, 杨艳梅, 张春艳, 张新宇. PTEN在三氧化二砷诱导肝癌细胞(SMMC-7721)凋亡中的作用[J]. 实用肿瘤学杂志, 2012, 26(4): 302-304.